fda tirzepatide shortage resolved oct 2 2024 US says Lilly's weight-loss drug is Tirzepatide Lawsuit Against the FDA:

Understanding Tirzepatide and Hormonal Shifts Tirzepatide is a dual-action medication known as a GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist

The COAs are transparent and we can verify independently

"Into the Woods 202223"

And its a philosophical problem not a data/scientific one

This is not the medication failing

Popular in sports and recovery beverages Integrated into weight-loss and energy drink formulations Strong adoption in low-calorie, clean-label drinks By End-Use Segment, Fat Loss Accounts for 38% of the Market Share Fat loss remains the most prominent end-use category with a 38% market share